• For children with growth hormone deficiency, once-weekly somatrogon injections were less of a burden than once-daily somatropin injections.
• The safety of weekly somatrogon was similar to that of daily somatropin.
• Compared with daily somatropin injections, children with growth hormone deficiency may be less likely to miss weekly somatrogon injections.
○ This is because weekly somatrogon injections were less of a burden and were less likely to interfere with daily activities compared with daily somatropin injections.
The purpose of this plain language summary is to help you to understand the findings from recent research.
• Somatrogon is used to treat the condition under study that is discussed in this summary. Approval varies by country; please check with your local provider for more details.
• The results of this study may differ from those of other studies. Health professionals should make treatment decisions based on all available evidence and not on the results of a single study.
This original scientific article on which this summary is based was published in the Journal of the Endocrine Society and can be accessed for free at: https://academic.oup.com/jes/article/6/10/bvac117/6695276. The details of the original article are as follows: Aristides K. Maniatis, Mauri Carakushansky, Sonya Galcheva, Gnanagurudasan Prakasam, Larry A. Fox, Adriana Dankovcikova, Jane Loftus, Andrew A. Palladino, Maria de los Angeles Resa, Carrie Turich Taylor, Mehul T. Dattani, Jan Lebl. Treatment burden of weekly somatrogon versus daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc 2022; 6(10): bvac117. DOI: 10.1210/jendso/bvac117.
